The world's only medicine treating spinal muscular atrophy (SMA) is entering the Chinese market, it was announced Sunday.
The drug is registered under the name Spinraza in the United States and European Union.
Available in more than 40 countries and regions, Spinraza is expected to bring new hope for those who living with SMA, a genetic disorder that affects muscle control, in China.
SMA affects between one in 6,000 and one in 10,000 in China, and about 95 per cent of the patients die 18 months after birth, doctors said.
Before the drug was available on the Chinese mainland, there was little effective therapy for the disease, and patients depended mainly on treatment such as respiratory and nutrition supports, said Xiong Hui, Beijing Medical Association rare disease committee member and Peking University First Hospital deputy director of pediatrics.